Tenaya Therapeutics is trading at $0.33, down 10.4%, amid broad risk-off pressure.

  • At 12:33 p.m. EST, XBI was reported down 5.19%, alongside sharp declines in major indexes; reliable current volume was unavailable.
  • Earnings did not identify the drop’s cause; the report showed a narrower quarterly loss, $1.7 million in collaboration revenue, and cash runway into Q4 2027.
  • Tenaya highlighted TN-401’s FDA RMAT designation and year-end clinical and regulatory updates, not clear explanations for the decline.